J
Jay L. Goldstein
Researcher at NorthShore University HealthSystem
Publications - 168
Citations - 11686
Jay L. Goldstein is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Celecoxib & Aspirin. The author has an hindex of 46, co-authored 167 publications receiving 11235 citations. Previous affiliations of Jay L. Goldstein include University of Illinois at Urbana–Champaign & University of Michigan.
Papers
More filters
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo
TL;DR: Among healthy subjects with lesion-free baseline VCEs, celecoxib was associated with significantly fewer small bowel mucosal breaks than naproxen plus omeprazole, and should be considered in future trials with VCE.
Journal ArticleDOI
Guideline for the management of ingested foreign bodies.
Glenn M. Eisen,Todd H. Baron,Jason A. Dominitz,Douglas O. Faigel,Jay L. Goldstein,John F. Johanson,J. Shawn Mallery,Hareth M. Raddawi,John J. Vargo,J. Patrick Waring,Robert D. Fanelli,Jo Wheeler-Harbough +11 more
TL;DR: This is one of a series of statements discussing the utilization of gastrointestinal endoscopy in common clinical situations where little or no data exist from well-designed prospective trials, emphasis is given to results from large series and reports from recognized experts.
Journal ArticleDOI
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh,John G. Fort,Jay L. Goldstein,Roger A. Levy,Patrick S. Hanrahan,Alfonso E. Bello,Lilia Andrade-Ortega,Carl B. Wallemark,Naurang M. Agrawal,Glenn M. Eisen,William F. Stenson,George Triadafilopoulos +11 more
TL;DR: In the treatment of osteoarthritis, celecoxib is as effective as the nonspecific NSAIDs naproxen and diclofenac, but has significantly fewer serious upper gastrointestinal events.
Journal ArticleDOI
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
Francis K.L. Chan,Angel Lanas,James M. Scheiman,Manuela F. Berger,Ha Nguyen,Jay L. Goldstein +5 more
TL;DR: Risk of clinical outcomes throughout the gastrointestinal tract was lower in patients treated with a COX-2-selective NSAID than in those receiving a non-selectives NSAID plus a PPI, and should encourage review of approaches to reduce risk of NSAID treatment.